Responding to global stimulant use: challenges and opportunities

M Farrell, NK Martin, E Stockings, A Bórquez… - The Lancet, 2019 - thelancet.com
We did a global review to synthesise data on the prevalence, harms, and interventions for
stimulant use, focusing specifically on the use of cocaine and amphetamines. Modelling …

Pharmacological treatment of methamphetamine/amphetamine dependence: a systematic review

KJ Siefried, LS Acheson, N Lintzeris, N Ezard - CNS drugs, 2020 - Springer
Background Stimulant drugs are second only to cannabis as the most widely used class of
illicit drug globally, accounting for 68 million past-year consumers. Dependence on …

Prescription psychostimulants for the treatment of stimulant use disorder: a systematic review and meta-analysis

VS Tardelli, A Bisaga, FB Arcadepani, G Gerra… - …, 2020 - Springer
Rationale Agonist-based pharmacologic intervention is an accepted approach in treatment
of opioid and tobacco use disorders. Objectives We conducted a systematic review and …

A qualitative examination of recent increases in methamphetamine use in a cohort of rural people who use drugs

ER Hansen, S Carvalho, M McDonald… - Drug and alcohol …, 2021 - Elsevier
Introduction Rising rates of methamphetamine use among populations using opioids is an
escalating public health concern. The purpose of this manuscript is to identify socioecologic …

Converging vulnerability factors for compulsive food and drug use

KM Serafine, LE O'Dell, EP Zorrilla - Neuropharmacology, 2021 - Elsevier
Highly palatable foods and substance of abuse have intersecting neurobiological, metabolic
and behavioral effects relevant for understanding vulnerability to conditions related to food …

[HTML][HTML] Past and current drug repurposing clinical trials to treat cognition in methamphetamine use: a scoping review of pharmacotherapy candidates

MMS Peters, CHJ Park, A Turner, AA Guerin… - Addiction …, 2023 - Elsevier
Globally, methamphetamine is one of the most widely used illicit substances. Despite this,
there are no Food and Drug Administration (FDA)-approved pharmacotherapies for treating …

Safety and tolerability of oral lisdexamfetamine in adults with methamphetamine dependence: a phase-2 dose-escalation study

N Ezard, B Clifford, A Dunlop, R Bruno, A Carr, Z Liu… - BMJ open, 2021 - bmjopen.bmj.com
Objectives To examine the safety of an agonist-type treatment, lisdexamfetamine (LDX), at
250 mg/day among adults with methamphetamine (MA) dependence. Design A dose …

Prevalence rates of personality disorder and its association with methamphetamine dependence in compulsory treatment facilities in China

C Zhang, T Luo, L Liu, H Dong, W Hao - Frontiers in Psychiatry, 2018 - frontiersin.org
Methamphetamine use is popular and rapidly increasing in China, and the co-occurrence of
personality disorders has an impact on treatment outcomes and may increase vulnerability …

[HTML][HTML] 20-year trends in Australian methamphetamine-related deaths, 2001–2020

O Stronach, P Dietze, M Livingston… - International Journal of …, 2024 - Elsevier
Background Over the past two decades methamphetamine-related harms have increased in
Australia. Previous analysis of methamphetamine-related deaths has covered limited …

[HTML][HTML] Review of methamphetamine use among Aboriginal and Torres Strait Islander people

M Snijder, S Kershaw - Aust Indig Health Bull, 2019 - healthbulletin.org.au
Methamphetamine is a stimulant drug, which means that it increases the activity of the
central nervous system and speeds up the chemical messages going between the brain and …